SCHEMBL23459964

SCHEMBL23459964

CCn1ncc(OC(C)C)c1C(C)=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.41
MEN1 O00255 3/20 0.41
NPC1 O15118 3/20 0.41
ATM Q13315 1/20 0.41
ALDH1A1 P00352 6/20 0.41
BLM P54132 2/20 0.41
POLB P06746 1/20 0.38
TSHR P16473 3/20 0.35
MAPK1 P28482 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
MAPT P10636 2/20 0.34
KDM4E B2RXH2 1/20 0.34
HCRTR1 O43613 1/20 0.33
HCRTR2 O43614 1/20 0.33
PKM P14618 1/20 0.33
HPGD P15428 1/20 0.33
RAB9A P51151 3/20 0.33
PDE4B Q07343 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16188065 0.71 MEN1 (0.38) KMT2AMEN1NPC1ATMALDH1A1
SCHEMBL23135542 0.70 LMNA (0.45) KMT2AMEN1NPC1ATMALDH1A1
SCHEMBL334488 0.66 LMNA (0.54) KMT2AMEN1NPC1ALDH1A1POLB
SCHEMBL23459922 0.66 NPC1 (0.41) KMT2AMEN1NPC1ALDH1A1POLB
SCHEMBL23188142 0.66 KMT2A (0.44) KMT2AMEN1NPC1ATMALDH1A1
SCHEMBL15897830 0.65 NPC1 (0.44) KMT2AMEN1NPC1ATMALDH1A1
SCHEMBL18412868 0.65 LMNA (0.44) KMT2AMEN1NPC1ALDH1A1POLB
SCHEMBL25623865 0.65 SMN1; SMN2 (0.40) KMT2AMEN1NPC1ATMALDH1A1
SCHEMBL25447709 0.65 LMNA (0.43) KMT2AMEN1NPC1ATMALDH1A1
SCHEMBL26906599 0.62 GAA (0.37) KMT2AMEN1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210163448-A1 QUINOLINE DERIVATIVES AS INHIBITORS OF AXL/MER RTK AND CSF1R QURIENT CO., LTD. (KR) 2021-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210163448-A1 QUINOLINE DERIVATIVES AS INHIBITORS OF AXL/MER RTK AND CSF1R CSF1R, CSF3R, FLT3 KMT2A 814/4885MEN1 793/4885NPC1 4073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.